Pancreatic Cancer Research

ResearcherUniversità Cattolica del Sacro CuoreActive in the last 2 years

Carmine Carbone

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5168-747X; OpenAlex author ID A5008175617, A5068933654. Sources: ClinicalTrials.gov.

Their work

Papers
28 (first author 1, last author 5)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
2
Collaborators
100
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 2 papers · 2018: 3 papers · 2019: none · 2020: none · 2021: 3 papers · 2022: 1 paper · 2023: 3 papers · 2024: 6 papers · 2025: 4 papers, 1 trial · 2026: 3 papers

Papers 28

  1. Fra-2 controls the response to the KRAS inhibitor MRTX-1133 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1073/pnas.2601788123↗
  2. Transcriptional and Epigenetic Plasticity Drive an Alternative Non-clonal Mechanism of Resistance to Kras G12D Inhibition in Pancreatic Cancer Last author DOI 10.34133/cancomm.0030↗
  3. High-fat diet imprints a macrophage-tumor CAMP-P2RX7 axis driving pancreatic cancer initiation, plasticity and metastasis Co-author DOI 10.64898/2026.02.10.703309↗
  4. Local ablation disrupts immune evasion in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2024.217327↗
  5. MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC. Co-author DOI 10.1038/s41586-025-08721-9↗
  6. Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic… Co-author DOI 10.1186/s13046-024-03238-x↗
  7. The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylation and favoring T lymphocyte infiltration. Co-author DOI 10.1186/s13046-024-03263-w↗
  8. An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2024.101411↗
  9. Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer. Co-author DOI 10.1038/s41467-024-54975-8↗
  10. Weighted gene co-expression network analysis reveals key stromal prognostic markers in pancreatic cancer. Co-author DOI 10.1038/s41598-024-82563-9↗
  11. Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC. Co-author DOI 10.1136/gutjnl-2023-329807↗
  12. Combined Nabpaclitaxel pressurized intraPeritoneal aerosol chemotherapy with systemic Nabpaclitaxel-Gemcitabine chemotherapy for pancreatic cancer peritoneal m… Co-author DOI 10.1515/pp-2024-0010↗
  13. Cellular collusion: cracking the code of immunosuppression and chemo resistance in PDAC. Co-author DOI 10.3389/fimmu.2024.1341079↗
  14. CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer. First author DOI 10.1038/s41416-022-02028-6↗
  15. Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer. Last author DOI 10.1186/s12967-023-04733-z↗
  16. KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy. Co-author DOI 10.3390/ijms24119313↗
  17. Spatial transcriptomics identified mucin-specific O-glycosylation as a key pathway in pancreatic cancer development and a promising therapeutic target Last author DOI 10.21203/rs.3.rs-2095432/v1↗
  18. Impact of COVID-19 on Pancreatic Cancer Research and the Path Forward. Co-author DOI 10.1053/j.gastro.2021.06.080↗
  19. Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with a… Co-author DOI 10.1136/jitc-2021-002876↗
  20. Pancreatic Cancer Patient-Derived Organoid Platforms: A Clinical Tool to Study Cell- and Non-Cell-Autonomous Mechanisms of Treatment Response. Co-author DOI 10.3389/fmed.2021.793144↗
  21. Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling. Co-author DOI 10.1038/ijo.2017.285↗
  22. MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity. Co-author DOI 10.21873/anticanres.12431↗
  23. Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance. Last author DOI 10.3390/ijms19113331↗
  24. A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma. Co-author DOI 10.1080/2162402x.2017.1322242↗
  25. EMT and Treatment Resistance in Pancreatic Cancer. Last author DOI 10.3390/cancers9090122↗
  26. Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. Co-author DOI 10.3389/fphar.2013.00056↗
  27. NF-κB as a target for pancreatic cancer therapy. Co-author DOI 10.1517/14728222.2011.645806↗
  28. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. Co-author DOI 10.1093/jnci/djr243↗

Trials 1

  1. Identification of New Theranostic Biomarkers of Pancreatic Tumor Progression Principal investigator NCT06574373↗

Closest collaborators

The 25 strongest of 100 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Geny Piro · 19 shared papers, 2013–2026 · strength 2.66
  2. Antonio Agostini · 15 shared papers, 2021–2026 · strength 2.62
  3. Giampaolo Tortora · 18 shared papers, 2013–2026 · strength 2.60
  4. Vincenzo Corbo · 14 shared papers, 2021–2026 · strength 2.36
  5. Francesco De Sanctis · 8 shared papers, 2021–2026 · strength 1.37
  6. Aldo Scarpa · 9 shared papers, 2017–2025 · strength 1.13
  7. Francesca Lupo · 5 shared papers, 2024–2025 · strength 0.86
  8. Alessia Caggiano · 5 shared papers, 2022–2026 · strength 0.86
  9. Sergio Alfieri · 5 shared papers, 2021–2024 · strength 0.75
  10. Rita Teresa Lawlor · 4 shared papers, 2023–2025 · strength 0.63
  11. Lisa Salvatore · 3 shared papers, 2024–2025 · strength 0.62
  12. Alberto Larghi · 4 shared papers, 2021–2025 · strength 0.59
  13. Davide Melisi · 8 shared papers, 2011–2018 · strength 0.56
  14. Vincenzo Bronte · 3 shared papers, 2024–2026 · strength 0.56
  15. Giuseppe Quero · 4 shared papers, 2021–2024 · strength 0.55
  16. Claudio Luchini · 3 shared papers, 2024–2026 · strength 0.53
  17. Claudio Sette · 3 shared papers, 2021–2026 · strength 0.50
  18. Sabrina L. D’Agosto · 3 shared papers, 2024–2025 · strength 0.48
  19. Lisa Veghini · 3 shared papers, 2024–2025 · strength 0.48
  20. Elena Fiorini · 3 shared papers, 2024–2025 · strength 0.48
  21. Gian Luca Rampioni Vinciguerra · 2 shared papers, 2026 · strength 0.46
  22. Pietro Delfino · 3 shared papers, 2021–2024 · strength 0.42
  23. Giuseppe Malleo · 3 shared papers, 2017–2025 · strength 0.40
  24. Chiara Musiu · 2 shared papers, 2024–2025 · strength 0.38
  25. Gabriella Lionetto · 2 shared papers, 2024–2025 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.